About Citius Pharmaceuticals (NASDAQ:CTXR)
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Industry, Sector and Symbol:
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Sector: Pharmaceuticals - NEC
- Symbol: NASDAQ:CTXR
- CUSIP: N/A
- Web: www.citiuspharma.com
- Trailing EPS: ($2.01)
- Return on Equity: -75.95%
- Return on Assets: -45.30%
- Outstanding Shares: 8,250,000
Frequently Asked Questions for Citius Pharmaceuticals (NASDAQ:CTXR)
What is Citius Pharmaceuticals' stock symbol?
Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."
When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?
Shares of Citius Pharmaceuticals reverse split on the morning of Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.
Who are some of Citius Pharmaceuticals' key competitors?
Some companies that are related to Citius Pharmaceuticals include Innocoll Holdings PLC (INNL), Sophiris Bio (SPHS), Female Health Company (The) (VERU), Aegerion Pharmaceuticals (AEGR), Juniper Pharmaceuticals (JNP), Amryt Pharma PLC (AMYT), SCYNEXIS (SCYX), Histogenics Corporation (HSGX), Evoke Pharma (EVOK), Azurrx Biopharm (AZRX), Pernix Therapeutics Holdings (PTX), Intellipharmaceutics International (IPCI), Apricus Biosciences (APRI), Concordia International Corp. (CXRX), Cellectar Biosciences (CLRB), Eyegate Pharmaceuticals (EYEG), Neuralstem (CUR) and Immune Pharmaceuticals (IMNP).
Who are Citius Pharmaceuticals' key executives?
Citius Pharmaceuticals' management team includes the folowing people:
- Leonard L. Mazur, Executive Chairman of the Board, Secretary (Age 71)
- Myron Z. Holubiak, President, Chief Executive Officer, Director (Age 69)
- Suren G. Dutia, Director (Age 72)
- Eugene Holuka, Director (Age 57)
- William J. Kane, Director (Age 72)
- Howard Safir, Director (Age 75)
- Carol A. Webb, Director (Age 69)
How do I buy Citius Pharmaceuticals stock?
Shares of Citius Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Citius Pharmaceuticals' stock price today?
One share of Citius Pharmaceuticals stock can currently be purchased for approximately $4.62.
How big of a company is Citius Pharmaceuticals?
Citius Pharmaceuticals has a market capitalization of $40.75 million.
How can I contact Citius Pharmaceuticals?
Citius Pharmaceuticals' mailing address is 11 Commerce Dr Fl 1, CRANFORD, NJ 07016-3501, United States. The company can be reached via phone at +1-908-9676676.
MarketBeat Community Rating for Citius Pharmaceuticals (NASDAQ CTXR)MarketBeat's community ratings are surveys of what our community members think about Citius Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Citius Pharmaceuticals (NASDAQ:CTXR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Citius Pharmaceuticals (NASDAQ:CTXR)
Analysts' Ratings History for Citius Pharmaceuticals (NASDAQ:CTXR)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Citius Pharmaceuticals (NASDAQ:CTXR)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Citius Pharmaceuticals (NASDAQ:CTXR)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Citius Pharmaceuticals (NASDAQ:CTXR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Citius Pharmaceuticals (NASDAQ CTXR)
Insider Trades by Quarter for Citius Pharmaceuticals (NASDAQ CTXR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/24/2017||Leonard L Mazur||Insider||Buy||11,000||$2.68||$29,480.00|| |
|8/8/2017||Leonard L Mazur||Insider||Buy||421,400||$4.13||$1,740,382.00|| |
Latest Headlines for Citius Pharmaceuticals (NASDAQ CTXR)
Citius Pharmaceuticals (NASDAQ CTXR) Chart for Wednesday, November, 22, 2017